Strictly Confidential — Qualified Investors Only

A New Asset Class in
Healthcare Finance:
Enforcement-Backed Returns +
Scalable Prescription Access

American Consultants Rx (ACRX) is building a nationwide platform that converts verified pharmacy benefit manager (PBM) violations into enforcement-backed recoveries — while simultaneously deploying a 400 million prescription card network generating recurring revenue at scale.

Capital Raise $30M+ in Strategic Capital
Request Investor Brief Schedule Confidential Call
2.1x–4.3x
Target ROI per Enforcement Case
$1.2T
Potential Recoverable Claims (10-Yr)
85%+
Win Rate at Enforcement Hearing
Section 01

Dual-Revenue Model. One Platform.

ACRX operates at the intersection of regulatory enforcement finance and consumer healthcare distribution — two self-reinforcing revenue streams that compound over time.

01
Revenue Stream One
Regulatory Enforcement Finance
ACRX identifies, validates, and monetizes statutory violations by pharmacy benefit managers — converting regulatory non-compliance into structured, enforcement-backed receivables with first-position repayment priority. Administrative action, not litigation. Statute-driven outcomes, not speculative bets.
02
Revenue Stream Two
Consumer Healthcare Distribution
A nationwide prescription savings card network deployed through 80,000+ community distribution partners generates recurring per-claim revenue. Each transaction validates PBM compliance data — feeding the enforcement pipeline with real-time intelligence that compounds both revenue streams simultaneously.
Short-Duration Receivables
6–12 month enforcement cycles with mandated repayment timelines. Predictable exit windows, not open-ended holds.
Recurring Rx Revenue
Per-prescription utilization revenue from 400M+ card deployments generates compounding cash flow independent of enforcement outcomes.
ESG-Aligned Impact
National-scale access to prescription savings for underserved communities. Regulatory enforcement accountability. Measurable healthcare impact at scale.
Section 02

Monetizing Verified PBM Violations

ACRX identifies and validates statutory violations by pharmacy benefit managers across four primary categories — each converting into structured enforcement actions with mandated restitution.

PBM Violation Categories
  • Spread Pricing — PBMs charge payers more than they reimburse pharmacies, capturing the spread as undisclosed profit.
  • Reimbursement Suppression — Systematic underpayment to pharmacies below cost, in violation of state MAC pricing statutes.
  • Denied / Unpaid Claims — Improper claim denials or delayed payments in violation of prompt payment statutes.
  • Rebate Misallocation — Manufacturer rebates not passed through to payers or plan beneficiaries as required by contract and statute.
Enforcement Conversion Path
Step 1
Administrative enforcement actions (not litigation) — filed with state regulatory bodies
Step 2
State-driven restitution mandates — outcomes governed by statute, not judicial discretion
Step 3
Structured receivables with first-position repayment priority under state enforcement authority
Investment Characteristics
Return Profile
2.1x – 4.3x
ROI per enforcement case
Duration
6–12 mo
Per enforcement cycle
Repayment Position
1st Position
Mandated by regulatory action
Win Rate
85%+
At hearing level
Pre-Hearing Settlement Rate
90%+
Majority resolved before formal hearing — no court delays
Key Differentiator
Unlike litigation finance, ACRX enforcement actions carry no court delays, no jury risk, and no legal fee burn. Regulatory enforcement operates through administrative channels with statute-mandated timelines.
"Outcomes are statute-driven, not speculative."
Section 03

400 Million Card Deployment Strategy

Scaling nationwide through 80,000+ distribution partners — healthcare providers, nonprofits, employer groups, and community networks — ACRX's prescription savings card program generates immediate recurring revenue while simultaneously feeding the AI enforcement pipeline with real-time transactional intelligence.

Distribution Partners 80,000+
Card Deployment Target 400M+
Network Type National
Revenue Model
$1.00–$1.25
Revenue Per Verified Claim
Per prescription filled through ACRX network
$400M–$500M
Projected Annual Revenue
At full network deployment scale
Real-Time
Data Pipeline
Compliance data feeds enforcement system continuously
Three Strategic Advantages of the Card Program
Immediate Cash Flow
Generates recurring per-claim revenue from day one of deployment — independent of enforcement timelines. Provides platform liquidity while enforcement cases mature.
Real-Time Intelligence Feed
Every transaction generates compliance data that feeds the AI enforcement system. Scale of card deployment = scale of violation detection pipeline. The two businesses compound each other.
Consumer Acquisition Engine
80,000+ community distribution partners create a consumer acquisition flywheel. Each partner extends geographic reach, deepens community trust, and strengthens the ACRX brand as a healthcare access platform.
"This is the liquidity engine behind the platform — recurring revenue that funds enforcement operations while the enforcement side compounds investor returns."
Section 04

AI-Powered Enforcement Infrastructure

ACRX integrates artificial intelligence across every stage of the enforcement and revenue cycle — from violation detection to yield modeling — operating across 54 U.S. jurisdictions through 168 enforcement nodes.

AI Integration Modules
Violation Detection & Pattern Recognition
Claim Validation & Documentation Automation
Regulatory Filing Automation
Yield Modeling & Investor Dashboards
ESG Reporting & Compliance Tracking
Real-Time Transactional Compliance Monitoring
Platform Scale
54
U.S. Jurisdictions
168
Enforcement Nodes
$1.2T
Potential Recoverable Claims
10-year outlook across all enforcement nodes
Section 05

Capital Deployment Framework

The $30M initial raise is designed as a strategic tranche to establish enforcement case inventory and expand card distribution — with a clear pathway to scale the platform toward $400M in total deployed capital as case outcomes are proven and distribution metrics are validated.

$30M+
Initial Capital Raise
Expandable to $400M
Enforcement Case Funding
$10M–$50M
AI Infrastructure & Technology
~$200M
Card Distribution Network Expansion
~$75M
Healthcare Innovation & ESG Programs
~$75M
Structure
Structured Receivables + Revenue Participation
Minimum Commitment
Available Upon Investor Brief Request
Investor Qualifications
Accredited Investors, Family Offices, Institutional
Section 06

Why Invest Now — The Timing Advantage

Three converging forces create an asymmetric entry window that is already closing as regulatory enforcement accelerates nationwide.

01
PBM Scrutiny at All-Time High
Congressional investigations, state AG actions, and federal legislation targeting PBM transparency have accelerated the regulatory enforcement environment. ACRX's enforcement infrastructure was built precisely for this moment.
02
Regulatory Enforcement Accelerating Nationwide
State-level PBM reform legislation has passed in 45+ states since 2020. Each new statute creates additional enforcement mandates — expanding ACRX's addressable recovery pool in real-time without additional capital deployment.
03
Massive Uncollected Claims Already Exist
Verified, documentable PBM violations representing trillions in potential recoveries exist today — not as future projections. ACRX's systems are deployed and processing. Capital converts immediately into active enforcement positions.
"This is not a future opportunity — it's already in motion."
Enforcement infrastructure deployed. Violations identified. Distribution network active. Capital converts to positions on day one.
Investor Access

Request Confidential Materials

Qualified investors may request the full investor brief, executive summary, and schedule a confidential discovery call with ACRX leadership.

Request Investor Brief
All submissions are reviewed by ACRX capital markets team within 1 business day.
Inquiry Received

Your request has been submitted to the ACRX capital markets team. A member of our team will contact you within 1 business day to discuss next steps and provide access to the full investor brief.

Schedule a Confidential Call
Prefer to speak directly? Schedule a confidential discovery call with Mr Charles Myrick, Founder/CEO of American Consultants Rx, to discuss the investment opportunity in detail.
Direct Email
CEO@ACRX.COM
Direct Line
404-977-0236
Principal
Mr Charles Myrick, Founder/CEO
Schedule via Calendly — Book a Confidential Call
This presentation is provided solely for informational purposes to prospective accredited investors. The information contained herein is confidential and proprietary. No portion of this document may be reproduced or distributed without express written consent of American Consultants Rx.